^
Association details:
| Biomarker: | EGFR mutation + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Regimen: | (paclitaxel + Tecentriq (atezolizumab) + Avastin (bevacizumab) + carboplatin) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study
Published date:
03/03/2023
Excerpt:
We retrospectively examined EGFR-mutant patients treated with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) therapy…in the ABCP group, the median PFS was significantly longer in the PD-L1–positive group than in the PD-L1–negative group (p = 0.047)....In EGFR-mutant patients, the efficacy of ABCP therapy was shown to be comparable to that of platinum-based chemotherapy after EGFR-TKI therapy. Notably, for PD-L1–positive patients, ABCP therapy may be expected to have a better clinical outcome than chemotherapy...
DOI:
https://doi.org/10.1111/1759-7714.14836
